Von Willebrand disease in children: diagnosis and management of a pediatric cohort in one single center in Argentina.

Abstract:

:Clinical and laboratory data of children with von Willebrand disease (VWD) types have been derived from retrospective studies and small case series. This article reports on the clinical and laboratory data of a large pediatric cohort in one single Argentinian center. The biological and clinical responses to desmopressin and replacement therapies are also described. Over a 15-year period, 194 of 1150 children (16.9%) were diagnosed as having type 1 VWD (80%), type 2 VWD (19%), and type 3 VWD (1%). The distribution of the different type 2 VWD subtypes was type 2A VWD, 43%; type 2B VWD, 32%; type 2M VWD, 19%; and type 2N VWD, 6%. Eighty patients with type 1 VWD and 12 patients with type 2 VWD were prospectively evaluated to desmopressin (DDAVP) response. A complete response was observed in all children with type 1 VWD, whereas 40% of the children with severe type 1 VWD and with type 2 VWD achieved a complete response. All the children who received DDAVP as prophylaxis or treatment for bleeding had good clinical evolution. Considering the restricted availability of specialized hemostasis centers, we believe our clinical and laboratory approach appropriate for the detection of patients with different types of VWD. Further studies are necessary to determine epidemiological aspects of VWD in Argentina to estimate the necessary facilities and trained personnel for the diagnosis and management of patients with VWD.

journal_name

Semin Thromb Hemost

authors

Bonduel M,Frontroth JP,Hepner M,Sciuccati G,Feliu-Torres A,Pieroni G

doi

10.1055/s-0031-1281043

subject

Has Abstract

pub_date

2011-07-01 00:00:00

pages

560-7

issue

5

eissn

0094-6176

issn

1098-9064

journal_volume

37

pub_type

杂志文章
  • Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.

    abstract::Low-molecular-weight heparins (LMWHs) are now universally accepted as drugs of choice for postsurgical prophylaxis and treatment of deep vein thrombosis (DVT). Currently, these agents are also being developed for the treatment of various cardiovascular conditions. Because of manufacturing differences, each of the LMWH...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2004-823007

    authors: Fareed J,Ma Q,Florian M,Maddineni J,Iqbal O,Hoppensteadt DA,Bick RL

    更新日期:2004-02-01 00:00:00

  • Concept of hypercoagulability: a review of its development, clinical application, and recent progress.

    abstract::There exist multiple clinical conditions, situations, and diseases in which persons appear to be at increased risk for thromboembolic phenomena, such as venous thrombosis and pulmonary embolus. Within this group of conditions, situations, or diseases, some are more clearly linked to thromboembolism that others. Simila...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-1004383

    authors: Kitchens CS

    更新日期:1985-07-01 00:00:00

  • Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.

    abstract::Analogues of L-arginine that are chemically modified at the terminal guanidino nitrogen group, such as Nomega-monomethy-L-arginine (L-NMMA), have been used for nitric oxide synthase inhibition. However, L-NMMA and other methylated L-arginine analogues are also endogenously formed. Among these, asymmetric dimethylargin...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-13210

    authors: Böger RH,Bode-Böger SM

    更新日期:2000-01-01 00:00:00

  • The Central Role of Fibrinolytic Response in Trauma-Induced Coagulopathy: A Hematologist's Perspective.

    abstract::Severe trauma is the leading cause of death globally. Though improved resuscitation, particularly early initiation, has reduced the 24-hour mortality rate, the overall morbidity and 30-day mortality remain high mostly due to massive hemorrhage and head injury in the early stages and sepsis and multiorgan failure later...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0039-3402428

    authors: Kwaan HC

    更新日期:2020-03-01 00:00:00

  • Consequences of homocysteine export and oxidation in the vascular system.

    abstract::The risk for arteriosclerosis and thrombosis of patients with severe hyperhomocysteinemia is reduced by homocysteine-lowering therapy. Whether this is the case in patients with mild hyperhomocysteinemia remains to be proved. Another challenge for researchers is to establish a satisfying pathological mechanism of the v...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-8467

    authors: Blom HJ

    更新日期:2000-01-01 00:00:00

  • Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.

    abstract:UNLABELLED:We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in Slovakia, where safe factor VIII (FVIII) concentrates have been used since 1990. A prospective study focused on inhibitor incidence in PUPs was established in 1997. Out of a total 61 PUPs born be...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,多中心研究

    doi:10.1055/s-0036-1581107

    authors: Batorova A,Jankovicova D,Morongova A,Bubanska E,Prigancova T,Horakova J,Machyniakova M,Cervenka J,Chandoga J,Böhmer D,Mistrik M

    更新日期:2016-07-01 00:00:00

  • Management strategies for optimal control of anticoagulation in patients with atrial fibrillation.

    abstract::Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for prevention of thromboembolism, in particular ischemic stroke. Many studies show the efficacy of this treatment but also that it is difficult to keep patients who use vitamin K antagonists in the proper treatment range. B...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0029-1240016

    authors: Levi M,de Peuter OR,Kamphuisen PW

    更新日期:2009-09-01 00:00:00

  • Using Artificial Intelligence to Manage Thrombosis Research, Diagnosis, and Clinical Management.

    abstract::Thrombosis development in either arterial or venous system remains a major cause of death and disability worldwide. This poorly controlled in vivo clotting could result in many severe complications including myocardial infarction, venous thromboembolism, stroke, and cerebral venous thrombosis, to name a few. These con...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-1697949

    authors: Mishra A,Ashraf MZ

    更新日期:2020-06-01 00:00:00

  • Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.

    abstract::The pharmacokinetics of heparin differ markedly from those of its fractions both in man and in experimental animal models. The route of administration determines the relative availability of different molecular species that exert the anti-Xa, anti-IIa, fibrinopeptide A generation inhibiting actions and the release of ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-1004360

    authors: Fareed J,Walenga JM,Williamson K,Emanuele RM,Kumar A,Hoppensteadt DA

    更新日期:1985-01-01 00:00:00

  • Disseminated intravascular coagulation in trauma injuries.

    abstract::Physical injuries, especially road traffic injuries, are a leading cause of death and morbidity worldwide, ranking fifth among the leading causes of death in the United States. Immediate and early trauma deaths are mainly determined by primary brain injuries and/or hemorrhages, whereas late mortality is caused by seco...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0030-1254047

    authors: Lippi G,Cervellin G

    更新日期:2010-06-01 00:00:00

  • Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis.

    abstract::Clinicians prescribing new oral anticoagulants (OACs; dabigatran, rivaroxaban, and apixaban) should be aware of the exclusion criteria related to bleeding risks defined in published clinical studies. At least a quarter of patients currently using warfarin have an exclusion criterion that may prevent easy transition to...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0031-1300948

    authors: Salmela B,Joutsi-Korhonen L,Armstrong E,Lassila R

    更新日期:2012-02-01 00:00:00

  • Management of venous thrombosis and pulmonary embolism after gynecological surgery.

    abstract::We experienced 23 cases of venous thrombosis after gynecological surgery for the past 12 years at Tokyo Women's Medical University Hospital, representing 0.345 % of all patients. Eighteen of the 23 cases had deep venous thrombosis (DVT) including five cases followed by pulmonary embolism (PE), and five cases had PE wi...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-996036

    authors: Adachi T,Nakabayashi M,Takeda Y

    更新日期:1998-01-01 00:00:00

  • Use of D-dimer assays in the diagnosis of venous thrombosis.

    abstract::In the course of fibrin formation, the D-domains of adjacent fibrin molecules within the fibrin polymer are covalently linked by factor XIIIa, leading to the formation of a D-domain dimer. Proteolysis of this cross-linked fibrin generates fibrin fragments D-dimer and E as terminal products. Fragment D-dimer therefore ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-13221

    authors: Dempfle CE

    更新日期:2000-01-01 00:00:00

  • Prothrombin-related antigens in human aortic intima.

    abstract::Most plasma proteins are present in both normal and atherosclerotic intima, and their concentrations in intimal interstitial fluid are directly related to plasma concentration and molecular size. All intimal samples also contain soluble fibrin-fibrinogen-related antigens, consisting of variable mixtures of fibrinogen ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-999030

    authors: Smith EB,Crosbie L,Carey S

    更新日期:1996-01-01 00:00:00

  • The Effect of BMI and Gender on Bleeding Events when Rivaroxaban Is Administered for Thromboprophylaxis Following Total Hip and Total Knee Arthroplasty.

    abstract::Rivaroxaban is approved in Europe and the United States for thromboprophylaxis following total joint arthroplasty. As the rate of obesity increases, confirming safety and efficacy in this patient population is paramount. This retrospective chart review assessed the efficacy and safety of rivaroxaban between two body m...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0038-1676319

    authors: Krauss ES,Cronin M,Dengler N,Simonson BG,Altner K,Daly M,Segal A

    更新日期:2019-03-01 00:00:00

  • Systolic heart failure: a prothrombotic state.

    abstract::Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0029-1234145

    authors: de Peuter OR,Kok WE,Torp-Pedersen C,Büller HR,Kamphuisen PW

    更新日期:2009-07-01 00:00:00

  • Venous thromboembolism as first manifestation of cancer.

    abstract::Numerous studies, performed in recent years, have provided the convincing demonstration that the incidence of newly diagnosed malignancy is increased among patients with unexplained venous thromboembolism during the first 6 to 12 months after the thromboembolic event. Among malignancies presenting with venous thromboe...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-994914

    authors: Monreal M,Prandoni P

    更新日期:1999-01-01 00:00:00

  • Angiostatin.

    abstract::The quiescent vascular system in the adult body represents the imbalanced net outcome of overproduction of endogenous angiogenesis inhibitors and reduced levels of angiogenic factors. While some endogenous inhibitors are expressed under physiological conditions, they can also be generated in association with tumor gro...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2004-822973

    authors: Cao Y,Xue L

    更新日期:2004-02-01 00:00:00

  • Impact of Asymptomatic Pulmonary Embolism on the Long-Term Prognosis of Patients with Deep Venous Thrombosis.

    abstract::Asymptomatic pulmonary embolism (PE) is present in at least one-third of patients with deep venous thrombosis (DVT). However, knowledge about its influence on the prognosis of patients is limited. The aim of this study was to assess the prognostic impact of asymptomatic PE in patients with DVT and to explore risk fact...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0036-1584351

    authors: Boc A,Vene N,Košmelj K,Mavri A

    更新日期:2017-02-01 00:00:00

  • Massive posttraumatic bleeding: epidemiology, causes, clinical features, and therapeutic management.

    abstract::Bleeding typically results as a consequence of derangements of primary hemostasis, secondary hemostasis, or both, and can be dramatically amplified by the presence of other predisposing conditions, especially inherited bleeding disorders. Life-threatening hemorrhages are, however, almost exclusively caused by penetrat...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0032-1328936

    authors: Lippi G,Favaloro EJ,Cervellin G

    更新日期:2013-02-01 00:00:00

  • Inhibition of platelet function: does it offer a chance of better cancer progression control?

    abstract::Thrombocytosis is frequently (10 to 57%) observed in cancer patients. Although the mechanisms underlying thrombocytosis are not yet fully elucidated, tumor-derived factors with thrombopoietin-like activity, growth factors, platelet-derived microparticles, and factors released from bone marrow endothelial cells as well...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-991540

    authors: Sierko E,Wojtukiewicz MZ

    更新日期:2007-10-01 00:00:00

  • Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.

    abstract::The present study revises the criteria of the Polycythemia Vera Group (PVSG) for the diagnoses of essential thrombocythemia (ET) and polycythemia vera (PV) in view of accumulating data on in vitro cultures of hematopoietic progenitors and by adding histopathology from bone marrow biopsies. The majority of ET patients ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 指南,杂志文章,实务指引

    doi:10.1055/s-2007-996107

    authors: Michiels JJ,Juvonen E

    更新日期:1997-01-01 00:00:00

  • Exposure to high altitude: a risk factor for venous thromboembolism?

    abstract::There are several genetic and acquired risk factors for venous thromboembolism. Exposure to high altitude (HA), either during air travel, ascension of mountains, or while engaging in sports activities, has been observed to result in a hypercoagulable state, thus predisposing to thromboembolic events. Although several ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0032-1301413

    authors: Gupta N,Ashraf MZ

    更新日期:2012-03-01 00:00:00

  • Anagrelide treatment in myeloproliferative disorders.

    abstract::Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2006-939437

    authors: Birgegard G

    更新日期:2006-04-01 00:00:00

  • The Clinical Relevance of Noncriteria Antiphospholipid Antibodies.

    abstract::While lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL)...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0037-1601328

    authors: Bertolaccini ML,Sanna G

    更新日期:2018-07-01 00:00:00

  • Hemophilia orthopedic management with emphasis on developing countries.

    abstract::The articular problems of patients with hemophilia begin in infancy when minor injuries result in hemarthroses. Early continuous prophylaxis (from cradle to college) is of paramount importance because the immature skeleton is very sensitive to the complications of hemophilia; severe structural deficiencies may develop...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2005-922223

    authors: Rodriguez-Merchan EC,Heim M

    更新日期:2005-11-01 00:00:00

  • Biologic tolerance of two different low molecular weight heparins.

    abstract::Heparin preparations have been used for prophylaxis and treatment of deep vein thrombosis for many years. Several biologic effects of heparin are known. Since 1978, there have been several reports about reversible elevation in serum values of AST and ALT in patients and healthy volunteers given heparin in small and hi...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1055/s-2007-1002654

    authors: Christiansen HM,Lassen MR,Borris LC,Sørensen JV,Rahr HB,Jørgensen LN,Jørgensen PW,Hauch O

    更新日期:1991-10-01 00:00:00

  • Fibrinolytic system in atherosclerosis.

    abstract::In this short review I have tried to report the literature findings and describe some of our observations on fibrinolysis and atherosclerosis. Although at this time it is difficult to state that diminished FA plays a pathogenic role in atherosclerosis, it certainly seems to represent a risk factor. ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1003541

    authors: Balkuv-Ulutin S

    更新日期:1986-04-01 00:00:00

  • Molecular mechanisms of megakaryocyte differentiation.

    abstract::Each bone marrow megakaryocyte (MK) releases thousands of platelets into the circulation, and the underlying molecular and cellular mechanisms recently have received intense scrutiny. Genetic studies are beginning to clarify the mechanisms by which transcription factors help distinguish MK progenitors from other blood...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2004-833474

    authors: Schulze H,Shivdasani RA

    更新日期:2004-08-01 00:00:00

  • Welcome to Seminars in Thrombosis and Hemostasis 2019-New (2017) Impact Factor and Most Highly Cited Papers.

    abstract:: ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 社论,历史文章

    doi:10.1055/s-0038-1677460

    authors: Favaloro EJ

    更新日期:2019-02-01 00:00:00